|

Value of Heart Rate Lowering Therapy in Acute Myocarditis

RECRUITINGSponsored by Assiut University
Actively Recruiting
SponsorAssiut University
Started2024-04-01
Est. completion2025-04-01
Eligibility
Age18 Years – 90 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06312891

Summary

To study the value of heart rate lowering therapy "pharmacological rest" on the short term in cases of myocarditis without LV dysfunction.

Eligibility

Age: 18 Years – 90 YearsHealthy volunteers accepted
Inclusion Criteria:

* Adults: ≥18 years of age.
* Presentation: at least one of the following:

  * Myopericarditis/ACS-like
  * MINOCA
  * Arrhythmias: brady or tachyarrhythmias.
  * Unexplained compensated acute cardiomyopathy (excluded ischemic, valvular, hypertensive, metabolic, and toxic causes of cardiomyopathy as indicated clinically).
* TTE: LVEF\>40%
* CMR-confirmed myo(peri)carditis (Lake Louise criteria)

Exclusion Criteria:

* • Rheumatic carditis.

  * Connective tissue diseases (-ve ANA).
  * Cancer chemotherapy.
  * Toxicity from immunotherapy.
  * Vaccine-related myocarditis.
  * Presence of coronary artery disease.
  * Peripartum (occurring during the last month of pregnancy or within 5 months after delivery)
  * ECG: atrial fibrillation/flutter.
  * Resuscitated sudden death.
  * Early/initial phase of decompensated heart failure.
  * Tamponade complicating pericarditis unless successfully managed.

Conditions2

Heart DiseaseMyocarditis

Browse More Trials

Heart Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.